UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment

Annals of oncology, 2017-09, Vol.28 (9), p.2149-2159

2017

Volltextzugriff (PDF)

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Clinical and translational gastroenterology, 2019-07, Vol.10 (7), p.e00056-e00056

2019

Volltextzugriff (PDF)

Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma

Annals of oncology, 2024-09, Vol.35 (9), p.780-791

2024

Volltextzugriff (PDF)

Tacrolimus and the Risk of Solid Cancers After Liver Transplant: A Dose Effect Relationship

American journal of transplantation, 2015-03, Vol.15 (3), p.678-686

2015

Volltextzugriff (PDF)

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial

Breast cancer research and treatment, 2014-03, Vol.110 (5), p.1148-1154

2014

Volltextzugriff (PDF)

Triplet chemotherapy plus cetuximab as first-line treatment in RAS wild-type metastatic colorectal carcinoma patients

Annals of oncology, 2019-07, Vol.30, p.iv26-iv27

2019

Volltextzugriff (PDF)

Liver stereotactic body radiotherapy: Clinical features and technical consequences, results. Which treatment machine in which situation?

Cancer radiothérapie, 2019-10

2019

Volltextzugriff (PDF)

Phase II efficacy and safety data for the MET inhibitor tepotinib in patients (pts) with sorafenib-treated advanced hepatocellular carcinoma (HCC)

Annals of oncology, 2018-10, Vol.29, p.viii235-viii235

2018

Volltextzugriff (PDF)

Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)

Annals of oncology, 2019-07, Vol.30, p.iv133-iv133

2019

Volltextzugriff (PDF)

Efficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met+ hepatocellular carcinoma (HCC) previously treated with sorafenib

Annals of oncology, 2018-11, Vol.29, p.ix48-ix48

2018

Volltextzugriff (PDF)

154 PREVALENCE OF ADENOMATOUS COLON POLYPS AFTER LIVER TRANSPLANTATION (LT): THE LEVEL OF IMMUNOSUPPRESSION MAKES THE DIFFERENCE

Journal of hepatology, 2013-04, Vol.58, p.S69-S69

2013

Volltextzugriff (PDF)

UCGI 28 Panirinox: A randomized phase II study assessing Panitumumab + FOLFIRINOX or mFOLFOX6 in RAS and BRAF wild type metastatic colorectal cancer patients (mCRC) selected from circulating DNA analysis

Annals of oncology, 2018-10, Vol.29, p.viii204-viii204

2018

Volltextzugriff (PDF)

O029 : HCV triggers Wnt paracrine signalling that modulates metabolic liver zonation

Journal of hepatology, 2015-04, Vol.62, p.S204-S204

2015

Volltextzugriff (PDF)

Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma - Trial in progress

Annals of oncology, 2018-06, Vol.29, p.v27-v28

2018

Volltextzugriff (PDF)

Management of immune-related toxicities associated with immune checkpoints inhibitors: Data from the multidisciplinary meeting « ToxImmun » in Eastern Occitania

La revue de medecine interne, 2021-05, Vol.42 (5), p.310

2021

Volltextzugriff (PDF)

Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial

ESMO open, 2021-12, Vol.6 (6), p.100318, Article 100318

2021

Volltextzugriff (PDF)

Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii156

2018

Volltextzugriff (PDF)

Intra arterial treatment of hepatocellular carcinoma: Comparison of MELD score variations between radio-embolization and chemo-embolization

Diagnostic and interventional imaging, 2019-11, Vol.100 (11), p.689-697

2019

Volltextzugriff (PDF)

CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation

Annals of oncology, 2018-10, Vol.29, p.viii267-viii268

2018

Volltextzugriff (PDF)

CA209-9DX: Phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation

Annals of oncology, 2018-11, Vol.29, p.ix65-ix65

2018

Volltextzugriff (PDF)

279: Alterations of hepatocyte metabolic identity are triggered by the hepatitis C virus through systemic wnt/β-catenin signalling

European journal of cancer (1990), 2014-07, Vol.50, p.S66-S66

2014

Volltextzugriff (PDF)

Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis

Endoscopy, 2009-06, Vol.41 (6), p.552-557

2009

Volltextzugriff (PDF)

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

The lancet oncology, 2017-12, Vol.18 (12), p.1624-1636

2017

Volltextzugriff (PDF)

Un diabète gestationnel peut en cacher un autre

Annales d'endocrinologie, 2016-09, Vol.77 (4), p.489-489

2016

Volltextzugriff (PDF)

Management of cancer-related thrombosis in the era of direct oral anticoagulants: A comprehensive review of the 2019 ITAC-CME clinical practice guidelines. On behalf of the Groupe Francophone Thrombose et Cancer (GFTC)

Journal de médecine vasculaire, 2020-02, Vol.45 (1), p.28-40

2020

Volltextzugriff (PDF)

1 – 25 von 166

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(148)
Mit Volltextzugriff
(149)

Publikationsform

Sprache

Englisch
(116)
Französisch
(55)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma

Tacrolimus and the Risk of Solid Cancers After Liver Transplant: A Dose Effect Relationship

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial

Triplet chemotherapy plus cetuximab as first-line treatment in RAS wild-type metastatic colorectal carcinoma patients

Liver stereotactic body radiotherapy: Clinical features and technical consequences, results. Which treatment machine in which situation?

Phase II efficacy and safety data for the MET inhibitor tepotinib in patients (pts) with sorafenib-treated advanced hepatocellular carcinoma (HCC)

Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)

Efficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met+ hepatocellular carcinoma (HCC) previously treated with sorafenib

154 PREVALENCE OF ADENOMATOUS COLON POLYPS AFTER LIVER TRANSPLANTATION (LT): THE LEVEL OF IMMUNOSUPPRESSION MAKES THE DIFFERENCE

UCGI 28 Panirinox: A randomized phase II study assessing Panitumumab + FOLFIRINOX or mFOLFOX6 in RAS and BRAF wild type metastatic colorectal cancer patients (mCRC) selected from circulating DNA analysis

O029 : HCV triggers Wnt paracrine signalling that modulates metabolic liver zonation

Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma - Trial in progress

Management of immune-related toxicities associated with immune checkpoints inhibitors: Data from the multidisciplinary meeting « ToxImmun » in Eastern Occitania

Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial

Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD

Intra arterial treatment of hepatocellular carcinoma: Comparison of MELD score variations between radio-embolization and chemo-embolization

CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation

CA209-9DX: Phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation

279: Alterations of hepatocyte metabolic identity are triggered by the hepatitis C virus through systemic wnt/β-catenin signalling

Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

Un diabète gestationnel peut en cacher un autre

Management of cancer-related thrombosis in the era of direct oral anticoagulants: A comprehensive review of the 2019 ITAC-CME clinical practice guidelines. On behalf of the Groupe Francophone Thrombose et Cancer (GFTC)

Suchergebnisse filtern